Saturday 17 October 2026
Export RXST’s income statement to Excel — free account
RxSight, Inc.
RXST Healthcare Medical Devices
RxSight, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $134.5 million, down 3.89% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS was flat and free cash flow fell 94.4%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
4.51
0.16
−3.43%
Follow RXST
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 3 | 3 | 5 |
+8 more TTM periods Free account |
| (17.35%) | (17.06%) | (13.99%) | (12.92%) | ||
| (14.19%) | (15.12%) | (12.36%) | (11.54%) | ||
ROIC |
(63.16%) | (70.00%) | (63.34%) | (58.67%) | |
Return on Tangible Assets |
(17.99%) | (17.59%) | (14.20%) | (13.01%) | |
Average Days of Receivables |
224.64 | 64.26 | 63.47 | 62.04 | |
Free Cash Flow per Share |
(0.65) | (0.52) | (0.47) | (0.54) | |
Free Cash Flow |
(27.16) | (21.58) | (19.34) | (22.19) | |
Capital Expenditures |
(4.43) | (4.01) | (3.83) | (3.54) | |
| Other line items | |||||
Cash ROIC |
(5.75%) | (4.45%) | (3.84%) | (4.41%) | |
Accounts Receivable Turnover |
2.39 | 4.77 | 5.03 | 5.74 | |
Accounts Payable Turnover |
5.92 | 4.12 | 6.40 | 8.93 | |
Inventory Turnover |
0.92 | 1.00 | 1.18 | 1.40 | |
Average Days of Payables |
80.67 | 88.75 | 61.42 | 34.67 | |
Days of Inventory on Hand |
471.93 | 434.39 | 366.03 | 297.22 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
28.75% | 29.54% | 28.67% | 27.34% | |
Selling, General and Administrative Expense of Revenue |
91.95% | 90.89% | 83.77% | 79.65% | |
Share Based Compensation of Revenue |
24.56% | 25.43% | 23.51% | 21.87% | |
Interest Coverage |
(3,936.64) | (3,459.12) | (2,536.37) | (2,393.89) | |
Operating CF/Net income |
0.48 | 0.38 | 0.40 | 0.52 | |
Depreciation/Fixed assets |
(0.29) | (0.35) | (0.40) | (0.49) | |
Capex/Depreciation |
1.10 | 0.86 | 0.73 | 0.55 | |
Revenue per Share |
3.07 | 3.09 | 3.29 | 3.47 | |
Operating CF per Share |
(0.55) | (0.43) | (0.38) | (0.46) | |
Capex per Share |
(0.11) | (0.10) | (0.09) | (0.09) | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.02 |
Columns are period end dates